REGARDS LABORATORY ANALYTES

|  |  |  |
| --- | --- | --- |
| Entire Cohort (baseline & 10-year) | Case/Cohort† | Other special populations (examples) |
| •        Lipid profile (total chol, HDL, LDL triglycerides) | D-dimer | HbA1c |
| •        Glucose | NT-proBNP | NMR Profile |
| •        C-reactive protein | IL-6 | TNF-α |
| •        Cystatin C | IL-8 | ICAM-1 |
| •        Urine Albumin | IL-10 | Aldosterone |
| •        Urine Creatinine\* | Adiponectin | Renin |
| •        CBC (Hgb, Hct, WBC, Plt)\* | Resistin | Leptin |
| •        BUN\* | Leptin | NT proBNP |
| •        Albumin | HGF | sCD14 |
| •        Insulin (minus people with diabetes) | Protein C |  |
| \*not measured on first 8000 participants | GGT, ALT, AST  |  |
|  | APOE genotyping |  |
|  | ABO genotyping |  |
|  | Sickle cell trait |  |
|  | DHEAS  |  |
|  | Galectin  |  |
|  | † 644 incident stroke through July 2010, 497 cognitive decline, 1100 cohort random sample |
| *\*\*Please inquire about additional analytes available via ancillary funding* |  |  |
|  |  |  |